MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
2101.51%
Quick Ratio
2101.51%
Cash Ratio
265.56%
Debt to Asset Ratio
4.12%
Unit: Thousand (K) dollars
Assets Breakdown
Marketable securities (note 5)
Marketable securities, long-term...
Cash and cash equivalents
Others
Liabilities Breakdown
Common shares, without par value...
Accumulated deficit
Additional paid-in capital
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
119,527
545,867
199,163
104,514
Marketable securities (note 5)
811,159
548,880
349,723
357,754
Other receivables
1,629
1,165
1,371
812
Prepaid expenses and other current assets
13,553
10,720
10,392
17,057
Total current assets
945,868
1,106,632
560,649
480,137
Marketable securities, long-term (note 5)
314,411
244,874
37,152
92,988
Operating lease right-of-use asset, net (note 6)
5,385
6,288
6,626
6,960
Property, plant and equipment, net
7,774
8,294
8,721
8,887
Deferred tax assets
14,361
12,417
12,864
11,750
Prepaid expenses, long-term
7,973
8,305
7,151
7,114
Total assets
1,295,772
1,386,810
633,163
607,836
Accounts payable and accrued liabilities (note 7)
43,671
38,254
40,260
36,840
Operating lease liability (note 6)
1,338
1,561
1,532
1,495
Total current liabilities
45,009
39,815
41,792
38,335
Operating lease liability, long-term (note 6)
5,080
5,930
6,412
6,832
Other liabilities, long-term
3,287
3,246
3,199
3,158
Total liabilities
53,376
48,991
51,403
48,325
Common shares, without par value unlimited shares authorized issued and outstanding 96,752,884 (december 31, 2025 - 80,010,790) (note 8)
2,426,619
2,421,833
1,598,571
1,475,371
Additional paid-in capital
276,851
264,879
228,234
223,782
Accumulated deficit
-1,458,418
-1,347,682
-1,245,380
-1,140,119
Accumulated other comprehensive income (loss)
-2,656
-1,211
335
477
Total shareholders' equity
1,242,396
1,337,819
581,760
559,511
Total liabilities and shareholders equity
1,295,772
1,386,810
633,163
607,836
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Marketable securities
(note 5)
$811,159K
(130.34%↑ Y/Y)
Cash and cash
equivalents
$119,527K
(-11.71%↓ Y/Y)
Prepaid expenses and
other current assets
$13,553K
(16.74%↑ Y/Y)
Other receivables
$1,629K
(48.50%↑ Y/Y)
Total current assets
$945,868K
(89.08%↑ Y/Y)
Marketable securities,
long-term (note 5)
$314,411K
(129.00%↑ Y/Y)
Deferred tax assets
$14,361K
(29.98%↑ Y/Y)
Prepaid expenses,
long-term
$7,973K
(-13.22%↓ Y/Y)
Property, plant and
equipment, net
$7,774K
(-15.55%↓ Y/Y)
Operating lease
right-of-use asset, net (note...
$5,385K
(-26.13%↓ Y/Y)
Total assets
$1,295,772K
(92.17%↑ Y/Y)
Total liabilities and
shareholders equity
$1,295,772K
(92.17%↑ Y/Y)
Total shareholders'
equity
$1,242,396K
(95.97%↑ Y/Y)
Total liabilities
$53,376K
(32.44%↑ Y/Y)
Accumulated deficit
-$1,458,418K
(-39.00%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$2,656K
(-2450.44%↓ Y/Y)
Common shares, without
par value unlimited...
$2,426,619K
(65.17%↑ Y/Y)
Total current
liabilities
$45,009K
(36.20%↑ Y/Y)
Operating lease
liability, long-term (note...
$5,080K
(-29.99%↓ Y/Y)
Other liabilities,
long-term
$3,287K
Additional paid-in capital
$276,851K
(29.43%↑ Y/Y)
Accounts payable and
accrued liabilities...
$43,671K
(38.25%↑ Y/Y)
Operating lease liability
(note 6)
$1,338K
(-8.29%↓ Y/Y)
Buy us a coffee
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)